About
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Visit company website
5 years, 5 months ago
Clinuvel Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 13.7% above its 200 day moving average.
From a valuation standpoint, the stock is 85.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 37.3.
Clinuvel Pharmaceuticals Limited's total revenue rose by 62.9% to $16M since the same quarter in the previous year.
Its net income has increased by 512.4% to $6M since the same quarter in the previous year.
Finally, its free cash flow grew by 93.6% to $4M since the same quarter in the previous year.
Based on the above factors, Clinuvel Pharmaceuticals Limited gets an overall score of 5/5.